In an interview with Targeted Oncology, Kellie Ryan, MPH, discussed the data on how physicians are currently using acalabrutinib as treatment of patients with mantle cell lymphoma in the real-world setting. She highlighted where she sees this research evolving in time.
In an interview with Targeted Oncology, Jason Westin, MD, discussed findings from a correlative analysis of the cytokine release syndrome and neurotoxicity associated with the chimeric antigen receptor T-cell therapy in the JULIET trial. He highlighted other important takeaways on the data on chimeric antigen receptor cells in diffuse large b-cell lymphoma.
The first-in-class AXL inhibitor bemcentinib plus checkpoint inhibitor pembrolizumab induced promising activity in patients with non–small cell lung cancer regardless of PD-L1 status, according to a phase II clinical trial. The data also suggest a greater benefit with the combination in patients who are AXL-positive.<br />
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed interim results from a phase II study of luspatercept as a treatment of anemia in patients with myelofibrosis, which he presented at the 2019 Annual Society of Hematology Annual Meeting.
In an interview with Targeted Oncology, Allison J. Moskowitz, MD, discussed the treatment options for patients with Hodgkin lymphoma and what research is still to come in the field. She also compared the treatment landscape of Hodgkin lymphoma with that of T-cell lymphomas, a rare subset of patients.
The aurora A kinase inhibitor alisertib plus the class I histone deacetylase inhibitor romidepsin is a safe combination for the treatment of patients with relapsed/refractory lymphomas, according to the findings from a phase I study whose results were published by Paolo Strati, MD, and colleagues in Haematologica.
In an interview with Targeted Oncology, Justin F. Gainor, MD, discussed the significance of identifying RET alterations in patients with non-small cell lung cancer and the prevalence of this molecular target. He also highlighted data supporting further evaluation of BLU-667.
In January 2020, the FDA approved new treatment options in gastrointestinal stromal tumors, bladder cancer, and epithelioid sarcoma. The FDA also granted several Priority Review Designations, orphan drug designations, and a Fast Track designation, as well as a Breakthrough Therapy designation.
The combination of talimogene laherparepvec plus pembrolizumab led to a promising objective response rate in patients with advanced sarcoma who typically have limited treatment options, according to a phase II clinical trial published in <em>JAMA Oncology</em>.
Continuous dosing of the MEK inhibitor binimetinib plus buparlisib, a PI3K inhibitor, demonstrated promising activity as treatment of patients with ovarian cancer harboring either a RAS or BRAF mutation, according to results from a phase Ib clinical trial.
In an interview with Targeted Oncology, Noa Biran, MD, discussed the findings from 2 clinical trials evaluating consolidation therapy post-transplant in patients with high-risk multiple myeloma.
In an interview with Targeted Oncology, Shoba A. Navai, MD, discussed the evolving role of CAR T-cell therapy in solid tumors, including sarcomas and how the efficacy and safety compare with CAR T cells in this space compared with hematologic malignancies.
The tyrosine kinase inhibitor lenvatinib demonstrated promising activity and safety in patients with advanced hepatocellular carcinoma in a retrospective multicenter observational analysis in Korea, according to a poster presentation at the 2020 Gastrointestinal Cancers Symposium.
In an interview with Targeted Oncology, Paul M. Barr, MD, discussed the rationale and preliminary findings for the phase I/II study evaluating umbralisib and ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia. He also explained how the role of combination therapy continues to evolve in this space.
The HER2-targeted antibody-drug conjugate trastuzumab deruxtecan demonstrated promising activity and manageable safety profile in patients with HER2-positive gastric or gastroesophageal junction cancer, meeting the primary end point of the study, according to a press release.
The CDK4/6 inhibitor ribociclib plus endocrine therapy with letrozole may induce molecular downstaging of disease in certain patients with high-risk, early-stage, hormone receptor–positive, HER2-negative breast cancer compared with multiagent chemotherapy, according to results from the randomized phase II CORALLEEN trial.
In an interview with Targeted Oncology, Elizabeth Mittendorf, MD, PhD, discussed the highlights from the 2019 San Antonio Breast Cancer Symposium for the treatment of patients with triple-negative breast cancer, as well as those with HER2-positive breast cancer. She also shared her thoughts on the key takeaways from the 2019 meeting.
Lenvatinib in combination with nivolumab demonstrated promising antitumor activity in patients with unresectable hepatocellular carcinoma with no new safety signals reported.
In an interview with Targeted Oncology, Vincent Chung, MD, discussed the findings from the pilot trial evaluating the addition of dietary supplements to combination chemotherapy in patients with unresectable pancreatic cancer. He also highlighted the importance of these findings and the next steps necessary to evaluate the role of supplements in pancreatic cancer further.
Atezolizumab failed to meet the primary end point, disease-free survival, as adjuvant monotherapy in patients with muscle-invasive urothelial cancer compared with observation in the phase III IMvigor010 clinical trial, according to a press release from Roche, developer of the drug.
In an interview with Targeted Oncology, Kaoru Tsuchiya, MD, discussed the results of the real-world study of lenvatinib in patients with unresectable hepatocellular carcinoma that are being presented at the 2020 Gastrointestinal Cancers Symposium.
A phase Ib/II clinical trial of the experimental anti-mitochondrial drug devimistat in combination with cisplatin and gemcitabine has been initiated in patients with biliary tract cancer, according to a press release from Rafael Pharmaceuticals, Inc. The company will collaborate with Michigan Medicine to proceed with the randomized multicenter clinical trial.
Myriad Genetics, Inc, has submitted a supplementary premarket approval application to the FDA for the myChoice CDx test for use in predicting outcomes for women with frontline platinum-responsive advanced ovarian cancer who are treated with niraparib, a PARP inhibitor, according to a press release from Myriad Genetics, Inc., the manufacturer of the test.
Neoadjuvant systemic therapy may enable patients with triple-negative breast cancer who are ineligible for breast conservation therapy to become eligible, according to a prespecified secondary analysis of the results from the phase III BrighTNess trial.
Entrectinib led to clinically meaningful responses in patients with NTRK-fusion-positive solid tumors, according to results from a pooled analysis of the phase I ALKA-372-001, the phase I STARTRK-1, and the phase II STARTRK-2 studies.
In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the rationale for evaluating a response-dependent treatment discontinuation strategy for older patients with previously untreated chronic lymphocytic leukemia. She highlighted the importance of determining an optimal discontinuation strategy in this patient population.
Dasatinib, a second-generation Abl-tyrosine kinase inhibitor, used concurrently with an intensive chemotherapy regimen yields superior outcomes compared with imatinib plus chemotherapy in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to the results from the first randomized phase III clinical trial comparing the 2 drugs in this patients <a>population</a>.
In an interview with Targeted Oncology, Richard Kim, MD, discussed the research from several trials that support the use of doublet and triplet regimens as treatment of patients with metastatic colorectal cancer harboring a BRAF mutation.
Bemcentinib in combination with pembrolizumab demonstrated clinical efficacy in the stage 1 portion of a phase II trial, which evaluated the combination in patients with non–small cell lung cancer who progressed on prior immune checkpoint inhibition, meeting the primary end point of the study.
The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib for the treatment of patients with <em>EGFR</em>-mutant non–small cell lung cancer who have progressed after treatment with osimertinib alone.